|
Synonyms: ATN-103 | PF-5230896
Compound class:
Antibody
Comment: Ozoralizumab is a trivalent albumin-binding nanobody that binds to and neutralises circulating TNFα. This biologic agent is being investigated for anti-inflammatory potential. The peptide sequence for ozoralizumab submitted in its WHO INN record is identical to SEQ ID NO: 96 (TNF30) in patent US8703131 [1], and identifies the albumin nanobody as ALB8. The patent claims a trivalent construct of TNF30-linker-ALB8-linker-TNF30.
|
| Immunopharmacology Comments |
| Ozoralizumab neutralises pro-inflammatory TNFα; TNFα being a causative immune modulator that exacerbates symptoms of rheumatoid arthritis and other autoimmune diseases. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Ozoralizumab has completed proof-of-concept Phase II clinical trial in RA (NCT00959036- in patients on a background of methotrexate) | |
